Serial Circulating Tumor DNA for Evaluating Early Response During Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Analysis of a Prospective Biomarker Study
X. Wang,T. Zhang,L. Deng,W. Wang,W. Liu,J. Wang,Y. R. Zhai,Q. Feng,J. Lv,Z. Xiao,D. Chen,Z. Zhou,N. Bi
DOI: https://doi.org/10.1016/j.ijrobp.2020.07.2242
2020-01-01
Abstract:Predicting tumor response after chemoradiotherapy in ESCC remains lacking. This analysis aimed to identify preliminary results of Circulating tumor DNA (ctDNA) markers in predicting tumor response after 4-week chemoradiotherapy for ESCC. We consecutively enrolled patients with unresectable esophageal squamous cell carcinoma, staged as clinical stage III, or clinical stage IV consisting of metastatic lymph nodes in the supraclavicular area according to AJCC 8th. Definitive chemoradiotherapy (CRT) were delivered concurrently with S-1 monotherapy or cisplatin plus paclitaxel-based doublet chemotherapy depending on physician's decision. Plasma samples were collected at different time point if obtained (1) pretreatment (pre-CRT), (2) the 4th week during chemoradiotherapy (mid CRT), (3) 4–8 weeks after chemoradiotherapy (post CRT), (4) 4-6 months in early follow-up time, and (5) disease progression. All patients were subjected to next-generation sequencing (NGS) with a 474 cancer-related gene panel. RECIST and computer tomography (CT) simulation at mid CRT evaluated tumor response. This trial was registered with ClinicalTrials.gov, number NCT0414465. We analyzed 79 serial plasma samples from 37 patients. ctDNA was detectable in 73% (27/37), 46% (12/26) and 31% (5/16) of pretreatment, during chemoradiotherapy and postchemoradiotherapy plasma samples. The most commonly mutated genes in our cohort are TP53 (85.7%, 24/28), CDKN2A (17.9%, 5/28), and ATR (17.9%, 5/28). At diagnosis (pre-CRT), median relative ctDNA abundance was associated with higher clinical T stage (T4 vs T3, 0.76 vs 0.18, p = 0.043). ctDNA concentration was significantly higher with increasing clinical stage (stage IV vs stage III, 109.1 vs 53.4, p = 0.042). Blood-based tumor mutation burden (bTMB) was higher with increasing clinical stage but was not statistically significant. A significant association between ctDNA concentration (r = 0.898, p<0.001) and bTMB (r = 0.737, p<0.001) with relative ctDNA abundance were detected at diagnosis. At mid CRT, overall response rate (ORR) was seen in 67.7% (22/33), including four complete response and 18 partial response. Among 25 patients with both plasma samples and CT evaluation at mid CRT, decreased ctDNA concentration was found in 56% (14/25), increased in 8%, and undetectable ctDNA concentration pre and mid CRT in 36% (9/25). In nine patients with persistently undetectable ctDNA concentration, ORR occurred in 77.8% (7/9). While, in 14 patients with decreased ctDNA concentration, 8 (57%) were associated with ORR. As early assessment, four-week CRT was associated with decreased ctDNA burden. The patients with undetectable ctDNA concentration pretreatment may have a better response to CRT due to relatively lower tumor burden. Radiomics analysis of CT simulation would be used to combine ctDNA assessment in predicting response and prognosis in ESCC. And more enrolled cases with long-term follow-up are needed.